Treatment regimen: Oral dosing at 1.8g/d and 9.0g/d. Outcome measures: The safety profile of a long-term treatment, the accumulation in the percentage of D-PUFA in plasma andred blood cell membrane, andpharmacokineticsof RT001 were studied. ...
Background: This study aims to evaluate the effect of subcutaneous (SC) elamipretide dosing on exercise performance using the 6 min walk test (6MWT), patient-reported outcomes measuring fatigue, functional assessments, and safety to guide the development of the Phase 3 trial. Methods: MMPOWER-...